Compare CRSP & OTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | OTEX |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.6B |
| IPO Year | 2016 | 1998 |
| Metric | CRSP | OTEX |
|---|---|---|
| Price | $50.21 | $23.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 10 |
| Target Price | ★ $70.29 | $36.10 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.92% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.94 |
| Revenue | $289,590,000.00 | ★ $2,815,241,000.00 |
| Revenue This Year | $807.72 | $2.82 |
| Revenue Next Year | $172.52 | $1.04 |
| P/E Ratio | ★ N/A | $11.93 |
| Revenue Growth | ★ 9169.85 | 22.88 |
| 52 Week Low | $35.38 | $20.00 |
| 52 Week High | $78.48 | $39.90 |
| Indicator | CRSP | OTEX |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 52.17 |
| Support Level | $44.82 | $21.87 |
| Resistance Level | $60.45 | $23.70 |
| Average True Range (ATR) | 2.49 | 1.05 |
| MACD | -0.37 | -0.02 |
| Stochastic Oscillator | 35.44 | 46.82 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.